Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126371191 | 12637119 | 1 | I | 20160725 | 20160809 | 20160809 | EXP | US-PAR PHARMACEUTICAL COMPANIES-2016SCPR015693 | PAR | LE N., ROSEN S.G.. SEVERE ELECTROLYTE ABNORMALITIES AFTER ZOLEDRONIC ACID TREATMENT FOR OSTEOPOROSIS. ENDOCRINE REVIEWS. 2014;35 | 0.00 | Y | 0.00000 | 20160809 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126371191 | 12637119 | 1 | PS | Zoledronic acid | ZOLEDRONIC ACID | 1 | Intravenous (not otherwise specified) | 5 MG, UNKNOWN | U | U | 202163 | 5 | MG | INJECTION |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126371191 | 12637119 | 1 | Osteoporosis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126371191 | 12637119 | OT |
| 126371191 | 12637119 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126371191 | 12637119 | Hypocalcaemia | |
| 126371191 | 12637119 | Hypokalaemia | |
| 126371191 | 12637119 | Hyponatraemia | |
| 126371191 | 12637119 | Hypophosphataemia | |
| 126371191 | 12637119 | Product use issue |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |